Key Clinical Summary: Advancing Pompe Care - Diagnosing Diverse LOPD Phenotypes

This is a micro-learning module summary of a presentation by Prof. John Vissing which you can find here.
Before participating, please read our CME and disclosure information which can be found here.

This activity is supported by an independent medical educational grant from Amicus Therapeutics. This online education program has been designed for healthcare professionals globally (excluding the USA).

1. Recognising the Heterogeneous and Multi-Systemic Nature of Late-Onset Pompe Disease (LOPD)

LOPD is a slowly progressive lysosomal storage disorder caused by partial deficiency of acid alpha-glucosidase (GAA), typically with residual enzyme activity of 1–30%.

Unlike infantile-onset Pompe disease, cardiomyopathy is rare; instead, disease evolves insidiously across multiple systems.

Core Clinical Features

• Proximal (limb-girdle) muscle weakness
• Early or disproportionate respiratory involvement, particularly diaphragmatic weakness

A striking clinical clue is an ambulatory patient requiring ventilatory support—highly unusual in other neuromuscular disorders

Broader Phenotypic Spectrum

Beyond skeletal muscle, LOPD may involve:

• Respiratory system (diaphragmatic weakness, nocturnal hypoventilation)
• CNS/vascular system (rare aneurysms, cognitive symptoms)
• Skeletal and axial musculature (rigid spine phenotype)
• Asymptomatic hyperCKemia

Clinical Insight: Respiratory symptoms (morning headaches, non-refreshing sleep, supine FVC drop) may precede marked limb weakness.

2. Differentiating LOPD from Limb-Girdle Muscular Dystrophies (LGMD)

LOPD is frequently misclassified as LGMD due to shared proximal weakness

Red Flags Suggesting LOPD in “Unclassified LGMD”

• Moderately elevated CK (typically 400–1,000 IU/L)
• Early or disproportionate respiratory insufficiency
• Vacuolar (not dystrophic) changes on biopsy, often subtle and inconsistent

Muscle biopsy may be normal or non-specific in up to 30% of cases and should not be used as a primary diagnostic test when LOPD is suspected.

Key Take-Home: Progressive respiratory decline out of proportion to limb weakness is a major diagnostic discriminator.

3. The Role of Imaging and Advanced Diagnostics

Muscle MRI is not first-line diagnostically but provides valuable pattern recognition and monitoring data.

Characteristic MRI findings include:

• Early involvement of paraspinal and hamstring muscles
• Relative preservation of anterior thigh and calf muscles
• Progressive fatty replacement over time

MR spectroscopy demonstrates increased glycogen in affected muscles and may support diagnosis and longitudinal monitoring.

4. Embedding a Multidisciplinary Diagnostic Pathway

To prevent irreversible muscle loss, early referral and streamlined testing are critical.

Recommended Diagnostic Approach
Step 1: Clinical Suspicion

• Limb-girdle pattern weakness
• Moderate CK elevation
• Respiratory red flags

Step 2: Refer to Specialized Neuromuscular Center

• LOPD is rare and best evaluated in experienced centers

Step 3: Confirmatory Testing

• If high suspicion → Dried blood spot (DBS) GAA enzyme testing or targeted GAA gene testing
• If broader differential → Next-generation sequencing (NGS), exome, or whole genome sequencing
• Muscle biopsy reserved for uncertain genetics or variant confirmation

Step 4: Multisystem Assessment

• Pulmonary function (upright and supine FVC)
• Sleep evaluation if indicated
• Cardiac assessment (baseline)
• MRI for baseline distribution and monitoring

Clinical Implications for Practice

LOPD is:

• Heterogeneous – ranging from hyperCKemia to ventilator-dependent respiratory weakness
• Progressive – with gradual but irreversible muscle degeneration
• Multi-systemic – affecting skeletal, respiratory, and occasionally CNS/vascular systems

Delayed recognition—especially when labeled as “unclassified LGMD”—results in avoidable diagnostic delay and muscle loss

Key Take-Home Messages

• Think LOPD in any adult with proximal weakness plus early respiratory involvement.
• Moderate CK elevation and subtle biopsy findings should raise suspicion.
• Avoid reliance on muscle biopsy as first-line testing.
• Use DBS or genetic testing early.
• Refer promptly to a specialized neuromuscular center.
• Embed a multidisciplinary pathway integrating neurology, pulmonology, genetics, and imaging.

Early recognition and structured diagnostic pathways are essential to prevent irreversible muscle damage and optimise long-term outcomes.

Content accurate at the time of publication.